Evidence map›Paper›PMID 39690425›Full record

ArticleRetrovirology2024

Declining trend of HTLV-1 among organ/ tissue donors in Iranian Tissue Bank between 2014-2021.

Arash Letafati, Sayed Hamidreza Mozhgani, Mehdi Norouzi, Amir Aboofazeli, Zahra Taghiabadi, Negar Zafarian, Saba Seyedi, Elnaz Mohammad Jaberi, Sedigheh Poursaleh, Maryam Karami and 2 more

Abstract read
In one paragraph

Article in Retrovirology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Epidemiology and Clinical Outcomes of HTLV-1: A Comprehensive Narrative Review of Endemic and Nonendemic Regions.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Arash LetafatiDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Sayed Hamidreza MozhganiDepartment of Microbiology and Virology, School of Public Health, Alborz University of Medical Sciences, Alborz, Iran.
Mehdi NorouziDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Amir AboofazeliResearch Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.
Zahra TaghiabadiResearch Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.
Negar ZafarianResearch Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.
Saba SeyediResearch Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.
Elnaz Mohammad JaberiResearch Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.
Sedigheh PoursalehIranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Maryam KaramiIranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Sheida SarrafzadehResearch Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.
Ahmadreza SadeghiIranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, Iran. sadeghi@tums.ac.ir.

Funding

Tehran University of Medical Sciences and Health Services 70490-427-4-1402
6 · The paper itself

Abstract

backgroundHuman T-cell Lymphotropic Virus type-1 (HTLV-1) infection is associated with serious disorders, including Adult T-cell Leukemia/Lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). In addition to sexual, vertical, parenteral, and blood transfusion, organ/tissue transplantation is considered as a transmission route of HTLV infection. Given the substantial risk of HTLV-1 transmission and the subsequent development of HAM/TSP (approximately 40%) in kidney transplant recipients, pre-transplant donor screening is crucial. The present study aimed to investigate the prevalence of HTLV-1 in potential organ/tissue donors referred to the Iranian Tissue Bank and Research Center (ITBRC). MATERIALS AND

methodsThe study population was potential organ and/or tissue donors referred to ITBRC between 2014 and 2021, including two groups of brain death (potential donors of organs and/or tissues) and circulatory death donors (potential tissue donors from Iranian Legal Medicine Organization). Initial screening was performed using enzyme-linked immunosorbent assay (ELISA), and positive cases were confirmed for HTLV-1 infection with polymerase chain reaction (PCR).

results111 out of 3,814 donors were positive for HTLV-1 (3%). The rate of positive tests between 2014 and 2017 was 6%, which was significantly higher than the positive tests percentage between 2017 and 2021 with 0.5% (P-value < 0.001). The rate of test positivity in females was 4% compared to 2% in males (P-value = 0.001). Furthermore, individuals diagnosed with brain death exhibited a significantly lower likelihood of HTLV-1 infection (0.2%) compared to cases with circulatory death (4%) (P-value < 0.001).

conclusionConsidering the contraindication of organ/tissue donation from donors with HTLV-1 positive test, these findings give an insight into the prevalence of HTLV-1 among potential organ/tissue donors in Iran. Moreover, the higher prevalence of HTLV-1 infection in circulatory death donors from Iranian Legal Medicine Organization urges for cautious evaluation in these donors.

Indexed as

HTLV-I InfectionsHuman T-lymphotropic virus 1Tissue BanksTissue DonorsAdolescentAdultFemaleHumansIranMaleMiddle AgedPrevalenceYoung AdultBrain deathCirculatory deathHTLV-1Organ transplantationTissue

Identifiers

PMID39690425
PMCPMC11650840

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.